statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli...

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Precision BioSciences price target raised by $28 at BTIG, here's why

Precision BioSciences (NASDAQ:DTIL - Free Report) had its price target boosted by HC Wainwright to $60.00 in a research report sent to investors on Thursday, Benzinga reports. The brokerage currently...

Precision BioSciences (NASDAQ:DTIL) Price Target Raised to $60.00 at HC Wainwright

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Akebia Therapeutics (AKBA Research Report) and Precision BioSciences...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings estimates for Precision BioSciences in a report issued on Thursday, March 28th. HC...

Brokers Issue Forecasts for Precision BioSciences, Inc.'s Q1 2025 Earnings (NASDAQ:DTIL)

Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) - Analysts at HC Wainwright issued their Q1 2025 EPS estimates for Precision BioSciences in a research report issued to clients and investors...

Research Analysts Offer Predictions for Precision BioSciences, Inc.'s Q1 2025 Earnings (NASDAQ:DTIL)

Precision BioSciences (NASDAQ:DTIL - Get Free Report) had its target price hoisted by analysts at HC Wainwright to $60.00 in a research report issued to clients and investors on Thursday, Benzinga...

HC Wainwright Increases Precision BioSciences (NASDAQ:DTIL) Price Target to $60.00

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Precision BioSciences (DTIL Research Report). The associated pric...

Buy Rating Affirmed for Precision BioSciences on Promising Gene Editing Prospects and Strong Financials

Precision BioSciences reports Q4 EPS ($4.06), consensus ($2.05)

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits...

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Volume	4.00
52-Wk High	$27.02
52-Wk Low	$8.25

DTIL Precision Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals